June 27, 2016 — Janssen Pharmaceuticals is accused of downplaying the risk of gynecomastia in the fifth Risperdal lawsuit to go to trial in Philadelphia.you
The plaintiff is a man who was born in 1998. He started taking Risperdal in 2003 to treat attention-deficit hyperactivity disorder and oppositional defiant disorder. He began growing breasts in 2004.
Risperdal was only approved for adults with schizophrenia until 2006, when it gained approval for children with autism-induced irritability.
The label reassured patients that gynecomastia was a “rare” side effect that occurred in fewer than one in 1,000 patients. However, a recent investigative report by Steven Brill highlighted the “creative math” Janssen Pharmaceuticals used to downplay gynecomastia.
Janssen made it seem like only 0.8% of boys developed gynecomastia, when in reality the number was closer to 4.5%. the drug-make is accused of failing to warn about gynecomastia to protect profits.
His mother filed the lawsuit in 2013 after seeing a lawyer’s ad on TV. His doctors tried to switch him to another medication but he continues taking generic Risperdal, according to The Legal Intelligencer.